The U.S. FDA has issued Form 483 with six observations after an inspection at Glenmark Pharmaceuticals Limited's formulation manufacturing facility based out of Baddi, India between June 13, 2022 and June 22, 2022.
The Company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.
Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 366.85 as compared to the previous close of Rs. 372.50. The total number of shares traded during the day was 28949 in over 1371 trades.
The stock hit an intraday high of Rs. 374.25 and intraday low of 362.65. The net turnover during the day was Rs. 10660699.00.